Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
58 hedge funds and large institutions have $85.6M invested in Astria Therapeutics in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 20 closing their positions.
168% more capital invested
Capital invested by funds: $32M → $85.6M (+$53.7M)
0.95% more ownership
Funds ownership: 7.88% → 8.83% (+0.95%)
7% less call options, than puts
Call options by funds: $269K | Put options by funds: $290K
5% less funds holding
Funds holding: 61 → 58 (-3)
15% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 20
48% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.9M |
| 2 |
PA
Perceptive Advisors
New York
|
+$12.5M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$8.74M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$7.68M |
| 5 |
VA
VR Adviser
New York
|
+$7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.74M |
| 2 |
BlackRock
New York
|
-$2.13M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.06M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$694K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$375K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
76
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$5K | -266 | Closed |
|
77
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$2K | -108 | Closed |
|
|
QCG
78
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$1K | -33 | Closed |
|
ATXS Hedge Fund Activity: Q2 2021 in Review
58 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q2 2021, worth a combined $85.6M — up 168% from $32M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ATXS and 17 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 12 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $12.9M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.74M sold.
- 58 institutional investors held Astria Therapeutics (ATXS) as of Q2 2021, down from 61 in Q1 2021.
- Funds reported $85.6M of Astria Therapeutics stock for Q2 2021, up 168% quarter-over-quarter.
- 17 funds opened new Astria Therapeutics positions in Q2 2021 and 20 closed out, a net change of -3 holders.
- The largest Astria Therapeutics buyer in Q2 2021 was RA Capital Management, an estimated $12.9M added.
- The largest Astria Therapeutics seller in Q2 2021 was Sphera Funds Management, an estimated $3.74M sold.
Based on aggregated 13F filings for Q2 2021.